The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an
exciting era of anticancer therapy. Durable responses can be seen in patients with …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …

Background The dynamics of PD-L1 expression may limit its use as a tissue-based
predictive biomarker. We sought to expand our understanding of the dynamics of PD-L1 …

Therapies targeting immune checkpoint molecules CTLA-4 and PD-1/PD-L1 have advanced
the field of cancer immunotherapy. New mAbs targeting different immune checkpoint …

Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on
certain lymphocytes that, with its ligand programmed death ligand 1 (PD-L1), helps to down …

Immunotherapies are revolutionizing cancer treatment by boosting the natural ability of the
immune system. In addition to antibodies against traditional checkpoint molecules or their …

PD-L1 is expressed in a percentage of lung cancer patients and those patients show
increased likelihood of response to PD-1 axis therapies. However, the methods and assays …

ABSTRACT ADAM10 and ADAM17 expression and soluble PD-L1 (sPD-L1) predict poor
prognosis in many malignancies, including in patients treated with PD-(L) 1 inhibitors. The …

Introduction Malignant pleural mesothelioma is a disease primarily associated with
exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are …

Cancer immunotherapy is arguably the most rapidly advancing realm of cancer treatment.
Glutathione peroxidase 4 (GPX4) has emerged as the vital enzyme to prevent lipid …